Terms: = Bone cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Prognosis
48 results:
1. Blasts with folded nuclei: A histopathologic finding in myeloid leukemia cutis with npm1 and FLT3 mutations.
Han S; Patel T; Garcia ML; Tirado M
J Cutan Pathol; 2024 Feb; 51(2):130-134. PubMed ID: 37866827
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and clinical significance of FLT3, npm1, DNMT3A and TP53 mutations in acute myeloid leukemia patients.
Ali AM; Salih GF
Mol Biol Rep; 2023 Oct; 50(10):8035-8048. PubMed ID: 37540457
[TBL] [Abstract] [Full Text] [Related]
3. Phenotypic clues that predict underlying cytogenetic/genetic abnormalities in myeloid malignancies: A contemporary review.
Stone M; Lilley CM; Tang G; Loghavi S; Mirza KM
Cytopathology; 2023 Nov; 34(6):530-541. PubMed ID: 37522274
[TBL] [Abstract] [Full Text] [Related]
4. Hypoplastic form of myelodysplastic neoplasm.
Votavová H; Lenertová Z; Votava T; Beličková M
Klin Onkol; 2023; 36(3):206-214. PubMed ID: 37353349
[TBL] [Abstract] [Full Text] [Related]
5. A global study for acute myeloid leukemia with RARG rearrangement.
Zhu HH; Qin YZ; Zhang ZL; Liu YJ; Wen LJ; You MJ; Zhang C; Such E; Luo H; Yuan HJ; Zhou HS; Liu HX; Xu R; Li J; Li JH; Hao JP; Jin J; Yu L; Zhang JY; Liu LP; Zhang LP; Huang RB; Shen SH; Gao SJ; Wang W; Yan XJ; Zhang XY; Du X; Chu XX; Yu YF; Wang Y; Mi YC; Lu Y; Cai Z; Su Z; Taussig DC; MacMahon S; Ball ED; Wang HY; Welch JS; Yin CC; Borthakur G; Sanz MA; Kantarjian HM; Huang JY; Hu J; Chen SN
Blood Adv; 2023 Jul; 7(13):2972-2982. PubMed ID: 36799929
[TBL] [Abstract] [Full Text] [Related]
6. Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.
Vasudevan Nampoothiri R; Tang K; Schuh A; Lam W; Maze D; Michelis FV; Chan S; Gupta V; Kim D; Kumar R; Lipton JH; Mattsson J; Minden M; Schimmer A; Sibai H; Viswabandya A; Yee K; Murphy T; Law AD
Eur J Haematol; 2023 Jun; 110(6):618-625. PubMed ID: 36732677
[TBL] [Abstract] [Full Text] [Related]
7. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF).
Maag AH; Swanton H; Kull M; Vegi NM; Feuring M
Cytometry A; 2023 Jul; 103(7):551-562. PubMed ID: 36647792
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation.
Zhao Q; Wang Y; Yu D; Leng JY; Zhao Y; Chu M; Xu Z; Ding H; Zhou J; Zhang T
BMC Cancer; 2022 Nov; 22(1):1229. PubMed ID: 36443709
[TBL] [Abstract] [Full Text] [Related]
9. Myeloid Sarcoma of the Breast as Blast Phase of JAK2-Mutated (Val617Phe Exon 14p) Essential Thrombocythemia: A Case Report and a Systematic Literature Review.
Pace M; Guadagno E; Russo D; Gencarelli A; Carlea A; Di Spiezio A; Bertuzzi C; Mascolo M; Grimaldi F; Insabato L
Pathobiology; 2023; 90(2):123-130. PubMed ID: 35850113
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical Significance of Low Expression of LncRNA CASC15 in Acute Myeloid Leukemia with npm1 Mutations].
Xia PH; Xu ZJ; Jin Y; Ma JC; Wen XM; Yuan Q; Leng JY; Qian J; Lin J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):659-670. PubMed ID: 35680788
[TBL] [Abstract] [Full Text] [Related]
11. [Analysis of clinical significance and prognostic impact of TET2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia].
Li YW; Guo Z; Wang LL; Zhou L; Lyu XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):241-246. PubMed ID: 35405783
[No Abstract] [Full Text] [Related]
12. npm1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A; Wakita S; Morita K; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Uoshima N; Kobayashi Y; Kawata E; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Kubota Y; Kimura S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Date K; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Ohashi K; Kanda Y; Yamaguchi H
Int J Hematol; 2022 Aug; 116(2):199-214. PubMed ID: 35377134
[TBL] [Abstract] [Full Text] [Related]
13. Immune-related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia.
Xu Q; Cao D; Fang B; Yan S; Hu Y; Guo T
Cancer Med; 2022 Sep; 11(17):3364-3380. PubMed ID: 35355427
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia.
Xue H; Gao H; Xia H; Li S; Li N; Duan Y; Ren Y; Zhang H; Liu J; Gao W
Medicine (Baltimore); 2021 Sep; 100(35):e26959. PubMed ID: 34477125
[TBL] [Abstract] [Full Text] [Related]
15. What is the likelihood of nonpulmonary metastasis occurring in the absence of lung metastasis in bone and soft tissue sarcoma? A nested case-control from a sarcoma referral centre.
Hasan O; Nasir M; Jessar M; Hashimi M; An Q; Miller BJ
J Surg Oncol; 2021 Dec; 124(8):1491-1498. PubMed ID: 34382687
[TBL] [Abstract] [Full Text] [Related]
16. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract] [Full Text] [Related]
17. AML in Saudi Arabia: Analysis According to the European LeukaemiaNet 2017 Cytogenetic Classification.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Elbjeirami WM
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e212-e220. PubMed ID: 32127298
[TBL] [Abstract] [Full Text] [Related]
18. Molecular MRD status and outcome after transplantation in npm1-mutated AML.
Dillon R; Hills R; Freeman S; Potter N; Jovanovic J; Ivey A; Kanda AS; Runglall M; Foot N; Valganon M; Khwaja A; Cavenagh J; Smith M; Ommen HB; Overgaard UM; Dennis M; Knapper S; Kaur H; Taussig D; Mehta P; Raj K; Novitzky-Basso I; Nikolousis E; Danby R; Krishnamurthy P; Hill K; Finnegan D; Alimam S; Hurst E; Johnson P; Khan A; Salim R; Craddock C; Spearing R; Gilkes A; Gale R; Burnett A; Russell NH; Grimwade D
Blood; 2020 Feb; 135(9):680-688. PubMed ID: 31932839
[TBL] [Abstract] [Full Text] [Related]
19. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and npm1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract] [Full Text] [Related]
20. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without npm1 mutation.
Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
[TBL] [Abstract] [Full Text] [Related]
[Next]
